Oncolytic Virus Immunotherapy
Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. Thi...
Wedi'i Gadw mewn:
| Fformat: | Online |
|---|---|
| Iaith: | Saesneg |
| Cyhoeddwyd: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Pynciau: | |
| Mynediad Ar-lein: | ONIX_20220506_9783036525495_238 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
| _version_ | 1869519085009633280 |
|---|---|
| collection | Directory of Open Access Books |
| description | Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities. |
| format | Online |
| id | doab-20.500.12854ir-81172 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-811722024-03-31T13:10:34Z Oncolytic Virus Immunotherapy Marchini, Antonio Ilkow, Carolina S. Melcher, Alan oncolytic viruses melanoma immunotherapy checkpoint inhibitors combinatory therapy reovirus oncolytic virus adenovirus oncolytic virotherapy targeting immunogenic cell death αvβ6 integrin oncolytic adenovirus cancer immunotherapy multi-stage immunostimulatory arming HSV-1 clinical trials newcastle disease virus NDV cancer immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 type I interferon herpes simplex virus retargeted virus tropism retargeting tumor checkpoint inhibitor vaccination antigen-agnostic vaccination HER2 parvovirus tumor microenvironment combination therapy glioblastoma pancreatic cancer colorectal cancer measles virus vector engineering immune checkpoint blockade antitumor immune response delivery genetic modification biomarkers personalized oncolyticvirotherapy class I HLA immunosurveillance immunoediting oncogenic signaling RAS DNA methyltransferase inhibitor (DNMTi) viral mimicry epigenetic silencing adoptive T cell therapy CAR T cell pancreatic ductal adenocarcinoma vesicular stomatitis virus small molecule cancer immune therapy cancer therapy n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities. 2022-05-06T11:32:56Z 2022-05-06T11:32:56Z 2022 book ONIX_20220506_9783036525495_238 9783036525495 9783036525488 https://directory.doabooks.org/handle/20.500.12854/81172 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/5203 https://mdpi.com/books/pdfview/book/5203 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2548-8 10.3390/books978-3-0365-2548-8 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036525495 9783036525488 366 Basel open access |
| spellingShingle | oncolytic viruses melanoma immunotherapy checkpoint inhibitors combinatory therapy reovirus oncolytic virus adenovirus oncolytic virotherapy targeting immunogenic cell death αvβ6 integrin oncolytic adenovirus cancer immunotherapy multi-stage immunostimulatory arming HSV-1 clinical trials newcastle disease virus NDV cancer immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 type I interferon herpes simplex virus retargeted virus tropism retargeting tumor checkpoint inhibitor vaccination antigen-agnostic vaccination HER2 parvovirus tumor microenvironment combination therapy glioblastoma pancreatic cancer colorectal cancer measles virus vector engineering immune checkpoint blockade antitumor immune response delivery genetic modification biomarkers personalized oncolyticvirotherapy class I HLA immunosurveillance immunoediting oncogenic signaling RAS DNA methyltransferase inhibitor (DNMTi) viral mimicry epigenetic silencing adoptive T cell therapy CAR T cell pancreatic ductal adenocarcinoma vesicular stomatitis virus small molecule cancer immune therapy cancer therapy n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine Oncolytic Virus Immunotherapy |
| title | Oncolytic Virus Immunotherapy |
| title_full | Oncolytic Virus Immunotherapy |
| title_fullStr | Oncolytic Virus Immunotherapy |
| title_full_unstemmed | Oncolytic Virus Immunotherapy |
| title_short | Oncolytic Virus Immunotherapy |
| title_sort | oncolytic virus immunotherapy |
| topic | oncolytic viruses melanoma immunotherapy checkpoint inhibitors combinatory therapy reovirus oncolytic virus adenovirus oncolytic virotherapy targeting immunogenic cell death αvβ6 integrin oncolytic adenovirus cancer immunotherapy multi-stage immunostimulatory arming HSV-1 clinical trials newcastle disease virus NDV cancer immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 type I interferon herpes simplex virus retargeted virus tropism retargeting tumor checkpoint inhibitor vaccination antigen-agnostic vaccination HER2 parvovirus tumor microenvironment combination therapy glioblastoma pancreatic cancer colorectal cancer measles virus vector engineering immune checkpoint blockade antitumor immune response delivery genetic modification biomarkers personalized oncolyticvirotherapy class I HLA immunosurveillance immunoediting oncogenic signaling RAS DNA methyltransferase inhibitor (DNMTi) viral mimicry epigenetic silencing adoptive T cell therapy CAR T cell pancreatic ductal adenocarcinoma vesicular stomatitis virus small molecule cancer immune therapy cancer therapy n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine |
| topic_facet | oncolytic viruses melanoma immunotherapy checkpoint inhibitors combinatory therapy reovirus oncolytic virus adenovirus oncolytic virotherapy targeting immunogenic cell death αvβ6 integrin oncolytic adenovirus cancer immunotherapy multi-stage immunostimulatory arming HSV-1 clinical trials newcastle disease virus NDV cancer immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 type I interferon herpes simplex virus retargeted virus tropism retargeting tumor checkpoint inhibitor vaccination antigen-agnostic vaccination HER2 parvovirus tumor microenvironment combination therapy glioblastoma pancreatic cancer colorectal cancer measles virus vector engineering immune checkpoint blockade antitumor immune response delivery genetic modification biomarkers personalized oncolyticvirotherapy class I HLA immunosurveillance immunoediting oncogenic signaling RAS DNA methyltransferase inhibitor (DNMTi) viral mimicry epigenetic silencing adoptive T cell therapy CAR T cell pancreatic ductal adenocarcinoma vesicular stomatitis virus small molecule cancer immune therapy cancer therapy n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine |
| url | ONIX_20220506_9783036525495_238 |